NCT02045264View on ClinicalTrials.gov

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2014

Primary Completion Date

February 27, 2014

Study Completion Date

February 27, 2014

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

Icatibant (30 mg)

On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments

Trial Locations (1)

91206

PAREXEL, Glendale